EDAP TMS S.A. Stock News

Edap Tms S.A. (NASDAQ:EDAP) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 39,100 shares, a decline of 45.5% from the October 31st total of 71,700 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading []

Geode Capital Management LLC reduced its position in shares of Edap Tms S.A. (NASDAQ:EDAP) by 15.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,764 shares of the medical equipment providers stock after selling 4,120 shares during the period. []

LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside

LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which is being held November 29 - December 2.

Edap Tms (NASDAQ:EDAP) had its target price decreased by B. Riley from $13.00 to $10.00 in a report published on Friday morning, The Fly reports. B. Riley currently has a buy rating on the medical equipment provider’s stock. A number of other equities research analysts also recently weighed in on EDAP. HC Wainwright dropped their […]

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia Gene Therapy Candidate Roche H

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2021 Results - Earnings Call Transcript

LYON, France, November 17, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the third quarter

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea Pharmaceuticals, Inc. (NASDAQ: A

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET

LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following inve

Favorable changes in market acceptance and reimbursement for the FocalOne have been obscured by pandemic headwinds.

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2021 Results - Earnings Call Transcript

LYON, France, August 25, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the second quarter o